Leonteq Securities AG’s Cytokinetics CYTK Stock Holding History

Leonteq Securities AG’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-160	Closed	-$10.5K	–	1301
2026 Q1	$10.5K	Hold	160	–	–	﹤0.01%	1068
2025 Q4	$10.2K	Buy	+160	New	+$9.95K	﹤0.01%	1194
2024 Q2	–	Sell	-70	Closed	-$4.91K	–	1219
2024 Q1	$4.91K	Hold	70	–	–	﹤0.01%	1085
2023 Q4	$5.84K	Buy	+70	New	+$2.54K	﹤0.01%	1039
2023 Q3	–	Sell	-1,200	Closed	-$39.1K	–	1217
2023 Q2	$39.1K	Hold	1,200	–	–	﹤0.01%	876
2023 Q1	$42.2K	Hold	1,200	–	–	﹤0.01%	836
2022 Q4	$55K	Hold	1,200	–	–	﹤0.01%	805
2022 Q3	$58.1K	Hold	1,200	–	–	﹤0.01%	771
2022 Q2	$47.1K	Hold	1,200	–	–	﹤0.01%	838
2022 Q1	$44.2K	Hold	1,200	–	–	﹤0.01%	887
2021 Q4	$54.7K	Buy	+1,200	New	+$46.3K	﹤0.01%	892

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Leonteq Securities AG's CYTK Position: Q2 2026 in Review

Leonteq Securities AG sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 160 shares — an estimated $10.5K sold.

Leonteq Securities AG first reported a position in CYTK in Q4 2021 and held it in 11 quarters. The position peaked at $58.1K in Q3 2022. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Leonteq Securities AG reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Leonteq Securities AG sold 160 Cytokinetics shares in Q2 2026, an estimated $10.5K.
Leonteq Securities AG first reported a position in Cytokinetics in Q4 2021 and held it in 11 quarters.
Leonteq Securities AG's Cytokinetics position peaked at $58.1K in Q3 2022.
479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.